XML 57 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 28, 2024
Income Tax Disclosure [Abstract]  
Schedule of income (loss) inclusive of equity-method earnings and before income taxes
Income (loss), inclusive of equity-method earnings (loss) and before income taxes, includes the following components (in thousands):
Year Ended
December 28,
2024
December 30,
2023
December 31,
2022
Domestic$(33,032)$(14,539)$32,088 
Foreign(121,781)(12,034)97,764 
$(154,813)$(26,573)$129,852 
Schedule of provision (benefit) for income taxes
The provision (benefit) for income taxes consists of the following (in thousands):
Year Ended
December 28,
2024
December 30,
2023
December 31,
2022
Current:
Domestic$(252)$3,291 $52,834 
Foreign6,978 15,599 3,856 
Total Current 6,726 18,890 56,690 
Deferred:
Domestic29,745 (9,036)(17,728)
Foreign (274)(1,911)(512)
Total Deferred29,471 (10,947)(18,240)
Provision for income taxes$36,197 $7,943 $38,450 
Schedule of reconciliation of federal statutory tax rate to effective tax rate
The reconciliation of the federal statutory tax rate to the Company’s effective tax rate is as follows:
Year Ended
December 28,
2024
December 30,
2023
December 31,
2022
Federal statutory rate21.0 %21.0 %21.0 %
Foreign tax rate benefit(9.2)(33.2)(6.2)
Current period valuation allowance(18.9)— — 
Change in prior period valuation allowance(12.9)(1.5)(0.3)
GILTI and Subpart F income, net of foreign tax credits(4.3)(24.2)16.5 
(Nondeductible) nontaxable foreign items(3.1)(26.0)4.5 
(Nondeductible) nontaxable domestic items(0.9)(3.6)0.7 
Nondeductible officer compensation(0.8)1.3 2.0 
Return to provision adjustments(0.3)16.5 (2.0)
State tax expense— (1.5)1.2 
Base erosion and anti-abuse tax— (7.4)— 
Other tax effects of equity compensation0.1 1.1 (0.3)
Foreign withholding taxes0.3 (2.2)0.4 
Excess tax benefit of stock-based compensation0.6 4.0 (1.1)
Release of prior year unrecognized tax benefits1.2 — (0.4)
Research and development tax credits4.2 26.9 (5.5)
Other(0.4)(1.1)(0.9)
Effective tax rate(23.4)%(29.9)%29.6 %
Schedule of significant components of deferred taxes Significant components of the Company’s deferred taxes as of December 28, 2024 and December 30, 2023 were as follows (in thousands):
December 28,
2024
December 30,
2023
Deferred tax assets:
Capitalized research and development$28,613 $27,402 
Tax credit carryforwards23,100 13,303 
Net operating loss carryforwards 17,484 6,911 
Intangible assets6,447 7,188 
Leases6,388 6,584 
Deferred income on shipments to distributors2,153 6,465 
Accrued liabilities2,063 2,859 
Other6,130 3,072 
92,378 73,784 
Less: Valuation allowance(60,760)(10,530)
31,618 63,254 
Deferred tax liabilities:
Intangible assets13,718 13,916 
Fixed assets6,812 8,353 
Leases6,053 6,238 
Prepaid expenses and other3,555 4,534 
Stock-based compensation1,001 — 
31,139 33,041 
Net deferred tax assets (liabilities)$479 $30,213 
Schedule of valuation allowance The following table summarizes the activity related to the valuation allowance for deferred tax assets (in thousands):
Balance at
Beginning of
Period
Additions
Charged to
Expenses
DeductionsBalance at
End of
 Period
Year ended December 28, 2024$10,530 $50,230 — $60,760 
Year ended December 30, 2023$9,409 $1,121 $— $10,530 
Year ended December 31, 2022$9,529 $792 $(912)$9,409 
Schedule of activity related to gross unrecognized tax benefits
The following table summarizes the activity related to gross unrecognized tax benefits (in thousands):
Year Ended
December 28,
2024
December 30,
2023
December 31,
2022
Beginning balance$4,868 $4,109 $3,677 
Additions based on tax positions related to current year970 737 872 
Additions based on tax positions related to prior years— 22 — 
Reductions based on tax positions related to prior years(5)— (6)
Reductions for tax positions as a result of a lapse of the applicable statute of limitations(1,406)— (434)
Ending balance$4,427 $4,868 $4,109